Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB0659 : HOUA-I  update : 2022/03/18
CommentHuman cell line derived from uterine cancer (endometrial cancer).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Ishiwata, Isamu
Originator Ishiwata, Isamu
Year of deposit 1991
Animal human < Mammals
Genus Homo
Species sapiens
Gender Female
Age at sampling 55 years
Tissue endometrium
Disease name Endometrial adenocarcinoma
Classification cancer
Year of origin 1982
Lifespan infinite
Morphology epithelial-like
Cellosaurus(Expasy) CVCL_3867
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives HamF12 + 15% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/3-4 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
Virus (HIV) (-)
Isozyme LD, NP
Chromosome mode 43-92(50) : /44(1),45(10),46(19),47(3),48(3),49(1)/
STR(human) OK
Images
deposit info
lot info
Reference information Reference 1
User's Publication 7


To topTop
Reference
1522  Ishieata, I., Soma, M., Ono, I., Nakaguchi, T., Ishiwata, C., Nozawa, S.and Ishikawa, H.  Biological Characterristics of Adenocarcinoma Cell Line ( HOUA-I ) and B-Lymphoblastoid Cell Line ( HOUA-II ) Established from The Same Tissue of Endmetrial Adenocarcinoma  Jikeikai Medical Journal  1989  36:303-315 

To topTop
User's Publication
13927  Xu D, Dong P, Xiong Y, Chen R, Konno Y, Ihira K, Yue J, Watari H.  PD-L1 Is a Tumor Suppressor in Aggressive Endometrial Cancer Cells and Its Expression Is Regulated by miR-216a and lncRNA MEG3  Front Cell Dev Biol  2020  8:598205  PubMed ID: 33363153
14241  Ihira K, Dong P, Xiong Y, Watari H, Konno Y, Hanley SJ, Noguchi M, Hirata N, Suizu F, Yamada T, Kudo M, Sakuragi N.  EZH2 inhibition suppresses endometrial cancer progression via miR-361/Twist axis  Oncotarget  2017  8(8):13509-13520  PubMed ID: 28088786
7708  Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, Sakuragi N.  MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1.  Mol. Cancer  2011  10:99  PubMed ID: 21851624
8772  Sugimoto T, Koizumi T, Sudo T, Yamaguchi S, Kojima A, Kumagai S, Nishimura R.  Correlative expression of cyclooxygenase-1 (Cox-1) and human epidermal growth factor receptor type-2 (Her-2) in endometrial cancer.  Kobe J Med Sci  2008  53:177-87  PubMed ID: 18204294
13831  Unoki M, Nakamura Y.  Methylation at CpG islands in intron 1 of EGR2 confers enhancer-like activity  FEBS Lett  2003  554(1-2):67-72  PubMed ID: 14596916
3101  Matsushima-Nishiu M, Unoki M, Ono K, Tsunoda T, Minaguchi T, Kuramoto H, Nishida M, Satoh T, Tanaka T, Nakamura Y  Growth and gene expression profile analyses of endometrial cancer cells expressing exogenous PTEN.  Cancer Res  2001  61:3741-9  PubMed ID: 11325847
1902  Shu Qin Liu, Kaoru Saijo, Makoto Kodama, Tadao Ohno  Intelligent matrices for tumor-specific cytotoxic T lymphocytes  Materials Science and Engineering: C  1994  2:61-65 



Back Back Return Top Page